Epiderali® Plus - Quellennachweise und Literaturverzeichnis
Aus rechtlichen Gründen weisen wir darauf hin: Die Informationen, die bzgl. der Wirkungen der Nähr- und Inhaltsstoffe in Onlife® gegeben werden, wurden sorgfältig recherchiert und aus Studien erarbeitet. Sie dienen der Zusammenfassung wissenschaftlicher Erkenntnisse und nicht der Konstatierung einer entsprechenden Wirksamkeit des Produkts. Die Studienergebnisse können nachgelesen werden:
Min Tao, Mcdowell, Saydah, Eberhardt (2008): Relationship of Polyunsaturated Fatty Acid Intake to Peripheral Neuropathy Among Adults With Diabetes in the National Health and Nutrition Examina tion Survey (NHANES) 1999–2004. Diabetes Care, Vol 31, No 1
Schilliti, Cucinotta, Fedele, Ingegnosi, Luca, Leotta (2014): Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients.
Abd El Baky, El-Baroty (2013): Healthy Benefit of Microalgal Bioactive Substances. Egypt Journal of Aquatic Science, Vol. 1, No. 1, 11-23.
A Role for Omega-3 Polyunsaturated Fatty Acid Supplements in Diabetic Neuropathy Peter Yee,1 Anne E. Weymouth,2 Erica L. Fletcher,1 and Algis J. Vingrys2Investigative Ophthalmology & Visual Science, March 2010, Vol. 51, No. 3
Alfonso M Durán, Lorena M Salto, Justin Câmara, Anamika Basu, Ivette Paquien, W Lawrence Beeson, Anthony Firek, Zaida Cordero-MacIntyre, Marino De León: Effects of omega-3 polyunsaturated fatty-acid supplementation on neuropathic pain symptoms and sphingosine levels in Mexican-Americans with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy , January 2019, Vol. 2019:12, pp 109–120
Wagnera, K.S.S. Lea, J. Yanga, and B.D. Hammocka: Epoxy fatty acids mediate analgesia in murine diabetic neuropathy. Eur J Pain. March 2017; 21(3): pp 456–465.
Min Tao, Md, Margaret A. Mcdowell, Sharon H. Saydah, Mark S. Eberhardt: Relationship of Polyunsaturated Fatty Acid Intake to Peripheral Neuropathy Among Adults With Diabetes in the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Diabetes Care, January 2008, Vol 31, No 1.
Da Young, Saswata Talukdar, Eun Ju Bae, Takeshi Imamura, Hidetaka Morinaga, WuQiang Fan, Pingping Li, Wendell J. Lu, Steven M. Watkins, and Jerrold M., Olefsky (2010): GPR120 is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-Inflammatory and Insulin Sensitizing Effects Cell. 142(5): pp 687–698.
Ko GD, Nowacki NB, Arseneau L, Eitel M, Hum A (2010): Omega-3 Fatty Acids for Neuropathic Pain: Case Series The Clinical Journal of Pain. Vol. 26, No 2, pp 168-172.
Ziegler D (2017): Diabetic peripheral and autonomic neuropathy. In: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ (Hrsg) Textbook of diabetes, 5. Aufl. Wiley-Blackwell, Oxford, S 580–608
Ziegler D, Keller J, Maier C, Pannek J (2018) DDG Praxisempfehlung. Diabetische Neuropathie. Diabetol Stoffwechsel 13 (Suppl 2), S230–S236.
Di Cesare Mannelli L, Pacini A, Corti F, Boccella S, Luongo L, Esposito E, et al. Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity. PLoS One. 2015;10
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U S A. 1995;92: 3376–80
Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002; 56:388–96.
Hesselink: New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide. The Open Pain Journal, 2012, 5, 12-23
Hesselink J. M.: Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection. International Medical Case Reports Journal. 2013;6(1):49–53.
Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor perox- isome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-9
Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2007;31:12–26
Shapiro H. Could n-3 polyunsaturated fatty acids reduce pathological pain by direct actions on the nervous system? Prostaglandins, leukotrienes, and essential fatty acids. 2003;68(3):219–24
Skaper SD, Facci GP. Mast cells, glia and neuroinflammation: partners in crime? Immunology. 2014;141: 314–27.
Skaper S. D., Facci L., Fusco M., Della Valle M. F., Zusso M., Costa B., et al. (2014). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
Visioli F, Giordano E, Nicod NM, Davalos A. Molecular targets of omega 3 and conjugated linoleic Fatty acids - „micromanaging“ cellular response. Front Physiol. 2012; 3:42 Inflammopharmacology 22, 79–94.